Who you are
Life Sciences & Pharma
Where does your molecule, process or formulation actually stand?
India's pharma sector is where patent law is argued hardest — Section 3(d), compulsory licensing, and a body of case law that decides what is patentable here rather than elsewhere. The work is landscaping before you spend, and knowing which side of the line your claim falls on.
Why businesses like yours call us
- Section 3(d) sits between you and a grant — incremental innovation is judged differently in India
- The register is crowded — landscaping before R&D spend, not after
- Licensing and technology transfer — the deal depends on rights clean enough to rely on
Where to start
- Entry product — Competitor IP Snapshot
- One firm throughout — you are not handed to another firm at the next rung.
Fee — scoped to your business, quoted in writing before you commit. No rate card, no hourly meter: the number you agree to is the number you pay.